FDA approves cryogenic ablation for menorrhagia
This article was originally published in Clinica
The US FDA has approved for sale what is claimed to be the first cryosurgical system for endometrial ablation. The Her Option Uterine cryoablation Therapy system, developed by CryoGen, was cleared via the agency's PMA process as a treatment for menorrhagia due to benign causes in pre-menopausal women.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.